Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/163068
Title: | Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors |
Author: | Lahiguera, Álvaro Hyrossová, Petra Figueras i Amat, Agnès Garzón, Diana Moreno, Roger Soto Cerrato, Vanessa McNeish, Iain Serra Elizalde, Violeta Lázaro García, Conxi Barretina, Pilar Brunet, Joan Menéndez, Javier A. Matias-Guiu, Xavier Vidal-Bel, August Villanueva Garatachea, Alberto Taylor-Harding, Barbie Tanaka, Hisashi Orsulic, Sandra Junza Martínez, Alexandra Yanes, Oscar Muñoz Pinedo, Cristina Palomero, Luis Pujana Genestar, M. Ángel Perales Losa, Carlos Viñals Canals, Francesc |
Keywords: | Tumors Metabolisme Oxidació Inhibidors enzimàtics Tumors Metabolism Oxidation Enzyme inhibitors |
Issue Date: | 13-May-2020 |
Publisher: | EMBO Press |
Abstract: | Mitochondrial metabolism and the generation of reactive oxygen species (ROS) contribute to the acquisition of DNA mutations and genomic instability in cancer. How genomic instability influences the metabolic capacity of cancer cells is nevertheless poorly understood. Here, we show that homologous recombination-defective (HRD) cancers rely on oxidative metabolism to supply NAD+ and ATP for poly(ADP-ribose) polymerase (PARP)-dependent DNA repair mechanisms. Studies in breast and ovarian cancer HRD models depict a metabolic shift that includes enhanced expression of the oxidative phosphorylation (OXPHOS) pathway and its key components and a decline in the glycolytic Warburg phenotype. Hence, HRD cells are more sensitive to metformin and NAD+ concentration changes. On the other hand, shifting from an OXPHOS to a highly glycolytic metabolism interferes with the sensitivity to PARP inhibitors (PARPi) in these HRD cells. This feature is associated with a weak response to PARP inhibition in patient-derived xenografts, emerging as a new mechanism to determine PARPi sensitivity. This study shows a mechanistic link between two major cancer hallmarks, which in turn suggests novel possibilities for specifically treating HRD cancers with OXPHOS inhibitors. |
Note: | Reproducció del document publicat a: https://doi.org/10.15252/emmm.201911217 |
It is part of: | EMBO Molecular Medicine, 2020, p. e11217 |
URI: | http://hdl.handle.net/2445/163068 |
Related resource: | https://doi.org/10.15252/emmm.201911217 |
ISSN: | 1757-4676 |
Appears in Collections: | Articles publicats en revistes (Infermeria Fonamental i Clínica) Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
701096.pdf | 1.71 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License